Currently Enrolling Trials
Bromfenac was cleared for marketing by the FDA on July 15, 1997. This provides an alternative to opioids for the management of acute pain. Bromfenac provides fast relief of acute pain without the side effects of opioid analgesics.
Possible adverse side effects include abdominal pain, headache, nausea, and vomiting.